January 28, 2015
Lanreotide demonstrated antitumor activity with a manageable safety profile in patients with pancreatic neuroendocrine tumors, according to a subgroup analysis of the CLARINET study presented at the Gastrointestinal Cancers Symposium.
The randomized, double blind CLARINET study included patients with metastatic grade 1 or grade 2 (Ki-67 <10%) non-functioning enteropancreatic neuroendocrine tumors. Patients underwent first-line treatment with 120 mg lanreotide (Somatuline Depot, Ipsen), a somatostatin analog, or placebo every 4 weeks for 96 weeks. Lanreotide was administered by deep subcutaneous injection.